Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04067011 · ClinicalTrials.gov registry record · Phase 2
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study
A Phase 2 study, sponsored by Emergent BioSolutions.
- Completed
- Registry status
- Phase 2
- Development phase
- 210
- Enrollment target
NCT04067011 is a Phase 2 study that has completed, run by Emergent BioSolutions. The registered enrollment target is 210 participants.
The verdict
NCT04067011, a Phase 2 study, has completed, sponsored by Emergent BioSolutions.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 210 participants
- Enrollment target
Study Summary
This study is designed to evaluate the pharmacokinetic (PK) profiles of ciprofloxacin or doxycycline when administered orally, prior to, and following, the intramuscular (IM) administration of a two-dose schedule of AV7909 administered two weeks apart.
Interventions
- BIOLOGICAL AV7909
- DRUG Ciprofloxacin 500Mg Tablet
- DRUG Doxycycline 100Mg Tablet
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 210 participants |
| Start Date | 2019-08-12 |
| Est. Completion | 2020-03-19 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04067011
The ClinicalTrials.gov registry entry for NCT04067011 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 210 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Emergent BioSolutions, which has 34 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which AV7909 is the first listed.
NCT04067011 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04067011 about?
NCT04067011 is a clinical study titled "Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study". This study is designed to evaluate the pharmacokinetic (PK) profiles of ciprofloxacin or doxycycline when administered orally, prior to, and following, the intramuscular (IM) administration of a two-dose schedule of AV7909 administered two weeks apart.
What is the current status of trial NCT04067011?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 210 participants. The study started on 2019-08-12. Estimated completion is 2020-03-19.
What interventions are being tested in trial NCT04067011?
The interventions under investigation include: AV7909 (BIOLOGICAL), Ciprofloxacin 500Mg Tablet (DRUG), Doxycycline 100Mg Tablet (DRUG).
Who is sponsoring clinical trial NCT04067011?
This trial is sponsored by Emergent BioSolutions, which has 34 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.